Full text is available at the source.
Abstract
Engineered lung-targeting lipid nanoparticles achieved functional mRNA delivery in approximately 20% of specific mesenchymal cells in fibrotic lungs.
- Fibroblast activation and differentiation into myofibroblasts contribute to excessive scarring in pulmonary fibrosis.
- Therapeutic delivery of SMAD7 mRNA inhibited fibroblast activation in human lung fibroblast cultures.
- In a preclinical model, treatment led to an approximately 40% reduction in histological collagen deposition.
- There was a significant reduction in lung hydroxyproline content, indicating decreased fibrosis.
- The vitronectin/vitronectin receptor axis may play a role in the uptake of the engineered lipid nanoparticles.
Simplified